Global market valuation was derived through revenue mapping and technology adoption analysis. The methodology included:
Identification of 50+ key technology providers and biopharmaceutical companies across North America, Europe, Asia-Pacific, and Latin America
Product mapping across biochemical products (enzymes, reagents, kits), genetic markers (SNP markers, STR markers, gene expression markers), and device categories (PCR systems, gene guns, gel electrophoresis assemblies)
Technique segmentation analysis covering artificial selection methodologies and gene splicing technologies including CRISPR-Cas9, TALENs, and zinc finger nucleases
Application mapping across agricultural biotechnology (crop improvement, livestock breeding, biofuels) and medical industry (gene therapy, diagnostics, drug discovery)
Analysis of reported and modeled annual revenues specific to genetic engineering portfolios
Coverage of manufacturers and technology providers representing 72-78% of global market share in 2024
Extrapolation using bottom-up (technology adoption volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for products, devices, techniques, and applications